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ABSTRACT
Objectives To comprehensively map the existing evidence 
assessing the impact of travel- related control measures 
for containment of the SARS- CoV-2/COVID-19 pandemic.
Design Rapid evidence map.
Data sources MEDLINE, Embase and Web of Science, and 
COVID-19 specific databases offered by the US Centers for 
Disease Control and Prevention and the WHO.
Eligibility criteria We included studies in human 
populations susceptible to SARS- CoV-2/COVID-19, 
SARS- CoV-1/severe acute respiratory syndrome, Middle 
East respiratory syndrome coronavirus/Middle East 
respiratory syndrome or influenza. Interventions of 
interest were travel- related control measures affecting 
travel across national or subnational borders. Outcomes 
of interest included infectious disease, screening, other 
health, economic and social outcomes. We considered 
all empirical studies that quantitatively evaluate impact 
available in Armenian, English, French, German, Italian and 
Russian based on the team’s language capacities.
Data extraction and synthesis We extracted data from 
included studies in a standardised manner and mapped 
them to a priori and (one) post hoc defined categories.
Results We included 122 studies assessing travel- related 
control measures. These studies were undertaken across 
the globe, most in the Western Pacific region (n=71). A 
large proportion of studies focused on COVID-19 (n=59), 
but a number of studies also examined SARS, MERS and 
influenza. We identified studies on border closures (n=3), 
entry/exit screening (n=31), travel- related quarantine 
(n=6), travel bans (n=8) and travel restrictions (n=25). 
Many addressed a bundle of travel- related control 
measures (n=49). Most studies assessed infectious 
disease (n=98) and/or screening- related (n=25) outcomes; 
we found only limited evidence on economic and social 
outcomes. Studies applied numerous methods, both 
inferential and descriptive in nature, ranging from simple 
observational methods to complex modelling techniques.
Conclusions We identified a heterogeneous and complex 
evidence base on travel- related control measures. While 
this map is not sufficient to assess the effectiveness 
of different measures, it outlines aspects regarding 
interventions and outcomes, as well as study methodology 
and reporting that could inform future research and 
evidence synthesis.
INTRODUCTION
In December 2019, the occurrence of the 
SARS- CoV-2 was reported in Wuhan, China. 
Over the next weeks, the virus and the asso-
ciated respiratory disease referred to as 
COVID-19 spread further into China and 
other parts of Asia including Japan, South 
Korea and Thailand.1 By mid- March 2020, 
when the WHO declared COVID-19 a global 
pandemic, cases had been observed in over 
100 countries and territories across the 
globe.2
According to WHO, various travel- 
related control measures, such as entry/exit 
screening, travel bans to and/or from specific 
Strengths and limitations of this study
 ► We applied systematic and standardised methods 
at all stages and have produced a comprehensive 
evidence map of travel- related control measures 
for containment of the SARS- CoV-2/COVID-19 
pandemic.
 ► For title/abstract and full- text screening, we de-
veloped guidance documents and conducted pilot-
ing exercises to ensure consistency among review 
authors; we additionally collected and clarified all 
uncertainties on a rolling basis through daily team 
calls.
 ► We conducted searches in three major health- 
related databases and two COVID- specific databas-
es; however, it is likely that most studies assessing 
economic and social outcomes are found in other 
databases.
 ► The unspecific and inconsistent reporting of prima-
ry studies with regard to interventions, especially 
when a package of control measures was inves-
tigated, meant that determining eligibility, as well 
as summarising and mapping these studies, was 
challenging.
 ► We did not include travel warning or travel advice 
in the evidence map, which limits the scope of this 
map.  on A
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areas within or between countries, and quarantine of trav-
ellers have since been implemented by most countries 
around the world to contain and mitigate the spread of 
SARS- CoV-2 and COVID-19.3 Following the early- stage 
responses in Asian countries, strict measures, such as 
border closures and drastic reductions in airline travel, 
have been put into place in most countries around the 
world, starting in February 2020 and continuing into May 
2020. While in the context of a rapidly evolving pandemic 
decisions often need to be made even in the absence of 
high quality evidence, efforts to identify and synthesise 
the best available evidence will help inform whether the 
currently implemented measures should be sustained, 
adapted or lifted. Where possible, decisions need to be 
based on evidence regarding the effectiveness of these 
measures in contributing to the control of the pandemic, 
as well as regarding the associated economic and social 
impacts. They will also need to take into account short- 
term and longer term costs, acceptability and feasibility 
of such measures.
Travel- related control measures have been assessed 
through systematic or narrative reviews in the context of 
previous epidemics and pandemics, such as influenza, 
severe acute respiratory syndrome (SARS- CoV-1/SARS) 
and Middle East respiratory syndrome (MERS- CoV/
MERS). Regarding the containment of influenza, these 
reviews have examined the effectiveness of a broad set 
of measures,4–6 as well as the effectiveness of specific 
measures, such as entry/exit screening6 7; they have also 
assessed the economic implications of various pharma-
ceutical and non- pharmaceutical interventions during 
influenza pandemics.8 9 Effectiveness of measures, such 
as international travel bans and entry/exit screening, 
have also been examined in reviews of SARS and 
MERS.7 10 To date and to the best of our knowledge, 
the evidence on travel- related control measures for the 
control of the current pandemic has not been systemat-
ically assessed.
In this paper, we aim to systematically identify and 
map the existing evidence assessing the impact of 
travel- related control measures (ie, border closures, 
travel restrictions and bans, entry and exit screening, 
quarantine/isolation of travellers crossing borders and 
multiple interventions combined) for containment of the 
SARS- CoV-2/COVID-19 pandemic, drawing on evidence 
from the current pandemic, as well as on evidence in rela-
tion to SARS, MERS and influenza. This evidence map 
was commissioned by the WHO to serve as an important 
resource for researchers and policymakers in providing 
an overview of the currently available evidence in relation 
to various travel- related control measures to contain the 
COVID-19 pandemic. In itself, the evidence map is not 
sufficient to assess the effectiveness of different measures. 
Instead, it provides an important basis for decisions 
regarding the need for and possibility to conduct primary 
research as well as more specific evidence synthesis (eg, 
regarding a specific category of control measures or a 
specific type of studies).
METHODS
Search strategy
We designed the evidence map in accordance with the 
Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses extension for Scoping Reviews (PRIS-
MA- ScR) reporting guideline, and implemented the 
entire project within ten days (see online supplemental 
file S1) for the completed PRISMA- ScR checklist). We 
searched the following databases: (1) Ovid MEDLINE 
ALL (1946–present); (2)  Embase. com (Elsevier); (3) 
Science Citation Index Expanded (1900–present), Social 
Sciences Citation Index (1900–present) and Emerging 
Sources Citation Index (2015–present) (Web of Science); 
(4) the US Centers for Disease Control and Prevention’s 
COVID-19 Research Articles Downloadable Database 
(includes published articles, as well as grey literature, 
such as preprints) and (5) WHO COVID-19 Database 
(includes published articles only).
The initial search strategy was developed for MEDLINE 
(see online supplemental file S2) and further adapted for 
the other databases. All database searches were conducted 
up to 3 May 2020. The search strategies were designed 
and conducted by an experienced information specialist. 
The searches were conducted in English. Where database 
functionality allowed for it, we limited the search results to 
Armenian, English, French, German, Italian and Russian, 
based on the language capacity of the research team and 
considered studies for inclusion published in all of these 
languages. We also conducted forward and backward cita-
tion searches of all relevant (systematic) reviews identified 
through the database searches (see online supplemental 
file S3) up to 6 May 2020 in Scopus (Elsevier).
Eligibility criteria
We determined eligibility of studies based on the inves-
tigated population/context, intervention, outcome and 
study type.
Regarding the population/context, this evidence 
map draws on direct evidence from human populations 
susceptible to the current SARS- CoV-2/COVID-19, as well 
as indirect evidence from a set of other relevant respira-
tory infectious diseases. To help define a set of diseases 
that is most similar and relevant to COVID-19, we used 
the following criteria: (1) diseases of viral origin; (2) 
mode of transmission primarily airborne via droplets/
aerosols (as well as person to person); (3) acute disease 
with the potential to cause an epidemic/pandemic; (4) 
similar clinical features (ie, non- specific febrile illness 
with the potential to develop into pneumonia and acute 
respiratory distress syndrome; difficult diagnosis based 
on clinical features during transmission- relevant phase, 
including the period prior to symptom development and 
during early- stage symptoms); and (5) unavailability of a 
vaccine and/or difficulty to contain an outbreak through 
vaccination. As a result, we considered:
 ► SARS- CoV-2/COVID-19.
 ► SARS- CoV-1/SARS.
 ► MERS- CoV/MERS.
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 ► Influenza.
Studies in all other populations/contexts, including 
evidence on infectious diseases less relevant to the current 
SARS- CoV-2/COVID-19 pandemic (eg, avian influenza, 
Ebola, meningitis, HIV/AIDS, tuberculosis, dengue, 
plague, cholera, fever, smallpox, measles or Zika virus) 
were excluded.
Regarding the intervention, we considered travel- 
related control measures affecting human travel across 
national or subnational borders, specifically:
 ► Closure of borders (borders closed to entry and/or 
exit).
 ► Travel bans (suspension of flights, ground crossing, 
ship itineraries, refusal of entry or travel and visa 
suspension/denial) between countries and between 
regions and large cities within countries.
 ► Travel restrictions (ie, varying levels of travel reduc-
tions) between countries and between regions and 
large cities within countries).
 ► Entry/exit screening (eg, temperature measurement, 
health questionnaire, thermography, physical exam-
ination, laboratory tests, passive observation and/or 
follow- up quarantine) at airports, ports, land borders 
and train stations.
 ► Quarantine/isolation of travellers from affected 
regions (at borders, at designated institutions or at 
home).
 ► Any combination of the above measures and/or with 
other control measures (eg, combination of border 
closure and school closure).
All other interventions were excluded. This comprised 
those not directly related to travel (eg, community- 
based quarantine, hygiene measures and bans on mass 
gatherings), those related to the movement of animals 
or goods, travel warnings or travel advice issued by the 
WHO or national governments, situations affecting 
travel but not representing travel- related control meas-
ures (eg, school holidays) and those solely concerned 
with the effectiveness of laboratory tests rather than 
their implementation as part of an entry/exit screening 
procedure.
Regarding outcomes, we considered those assessing the 
quantitative impacts of the interventions on:
 ► Infectious disease outcomes (eg, number/proportion 
of cases, number/proportion of deaths, time to/delay 
in epidemic arrival or peak, reproduction number, 
healthcare demand and utilisation).
 ► Screening outcomes (eg, number/proportion of 
persons screened and number/proportion of those 
screened identified as cases).
 ► Other health outcomes (eg, psychosocial impact).
 ► Economic outcomes (eg, travel volumes, costs of meas-
ures implemented and losses to different economic 
sectors).
 ► Social outcomes (eg, stigmatisation/discrimination of 
foreigners, xenophobia and migration volumes).
All other outcomes, such as those on the human rights 
and legal implications of interventions, were excluded.
Regarding study types, we considered all types of empir-
ical studies that quantitatively evaluate impact (eg, epide-
miological, modelling, simulations and econometric 
studies). All other study types, including qualitative 
studies, diagnostic studies focused on test performance 
and non- empirical studies (eg, commentaries, narrative 
and systematic reviews) were excluded.
Study selection
After deduplication, all titles and abstracts were screened 
by one reviewer (shared among several team members), 
excluding only those studies that were clearly irrelevant. 
For all studies deemed potentially relevant or unclear at 
the title/abstract screening stage, one reviewer screened 
the full text. At this stage, a final decision regarding eligi-
bility was made. We adopted a very inclusive approach: 
any unclear cases were discussed with a second reviewer, 
and remaining uncertainties were resolved with involve-
ment of a third reviewer and/or the whole review team. 
In addition, all studies excluded at the full- text screening 
stage based on the intervention (ie, not addressing travel- 
related control measures) were double- checked by a 
second reviewer to make sure that no relevant studies 
were excluded.
We used Endnote to manage collection and dedupli-
cation of records. For title and abstract screening, we 
used Rayyan, a web- based application designed for cita-
tion screening for systematic reviews.11 We documented 
reasons for the exclusion of full texts and reported those 
using Microsoft Excel.
For both the title/abstract and full- text screening stages, 
we developed screening guidance forms to ensure that all 
reviewers screen similarly and consistently. We discussed 
inconsistencies and challenges encountered within the 
review team, after having screened approximately 300 
titles/abstracts and 50 full texts and subsequently refined 
the screening guidance. We additionally collected and 
clarified all uncertainties in screening on a rolling basis. 
These were discussed in daily online meetings to ensure 
consistency in screening across multiple reviewers and 
that any questions and comments were addressed.
Data extraction
One reviewer extracted study characteristics and data 
into the predefined categories of the data extraction 
form in Microsoft Excel (see online supplemental file 
S4). The extraction form was pilot- tested in the review 
team. The following categories were covered by the 
extraction form: population, setting and context; char-
acterisation of the respiratory pathogen/disease (ie, 
SARS- CoV-2/COVID-19, SARS CoV-1/SARS, MERS 
CoV/MERS and influenza), types of interventions (eg, 
entry/exit screening, border closure, quarantine of trav-
ellers and travel bans), comparisons (where available), 
outcomes of interest (eg, health, economic and social 
impact) and study designs (eg, epidemiological study 
and modelling study).
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Mapping
We charted the extracted data based on categories 
and present findings in a tabular, narrative or graph-
ical manner. Most of these categories were defined 
a priori, while one category, namely, geographical 
setting, was adapted post hoc. Specifically, we sought to 
define, summarise and present clusters of studies based 
on the pathogen/disease (ie, SARS- CoV-2/COVID-
19, SARS- CoV-1/SARS, MERS- CoV/MERS and influ-
enza), type of intervention (border closure, entry/exist 
screening including follow- up measures, such as isolation 
of positive cases, travel ban, travel- related quarantine in 
the absence of entry/exit screening, travel restrictions 
and multiple travel- related control measures combined), 
timing of the intervention (ie, early phase, local transmis-
sion phase, postpeak phase and unclear phase), outcomes 
of interest (ie, infectious disease outcomes, screening 
outcomes, other health outcomes, economic and social 
outcomes) and study designs (eg, epidemiologic study 
and modelling study). All data presented in the tables, 
text and graphics were double- checked by a second 
reviewer with an emphasis on accuracy in reporting on 
populations, interventions and outcomes and in relation 
to consistency of presentation.
Patient and public involvement
Considering the time constraints and the nature of this 
research (ie, a rapid systematic evidence map), it was 
conducted without patient and public involvement.
RESULTS
Database searches yielded a total of 4928 unique records. 
Through snowballing of reviews identified through the 
database searches, we identified an additional 1700 
studies. During the title/abstract screening stage, we 
excluded 4445 records as clearly irrelevant. We subse-
quently assessed the full texts of 483 records and excluded 
another 361 records. Overall, we included 122 studies in 
this evidence map (see online supplemental file S5 for 
the full list). Of these, 80 were journal articles, 41 were 
preprints and 1 was a report. Figure 1 provides an over-
view of our searching and screening procedures.
Characteristics of included studies
The 122 included studies were characterised by substan-
tial heterogeneity in relation to the countries and popu-
lations targeted, the diseases addressed, the types of 
travel- related control measures examined (sometimes 
assessed against a range of other interventions to contain 
an epidemic/pandemic) and the numerous outcomes 
assessed. They comprise both studies that are inferen-
tial in nature and studies that are descriptive in nature, 
varying greatly in the specific methods applied; notably, 
many of the studies addressing COVID-19 were preprints. 
We summarise these aspects below and provide a descrip-
tion of each study in table 1.
Countries and settings
Included studies assessed interventions across the globe, 
including, according to WHO world regions, from the 
Western Pacific Region (WPR) (n=71), the Southeast Asia 
region (n=5), the region of the Americas (n=12), the Euro-
pean region (EUR) (n=8), and the African region (AFR) 
(n=2). None of the studies included in this evidence map 
was conducted in a country of the Eastern Mediterranean 
Region (EMR). The specific countries in which inter-
ventions were implemented are listed in table 1 (under 
Figure 1 Flow chart of studies identified and included during different stages of searching and screening.
 on A
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‘regions protected by travel related measure’). Several 
modelling studies looked at hypothetical regions (n=16).
Of the identified interventions, some were imple-
mented in island states (n=24) or in what we define 
quasi- island states (n=9), such as the UK or Hong Kong, 
which have limited land borders connected through, for 
example, a tunnel. Most interventions were implemented 
in non- island states (n=74). The remaining interventions 
assessed hypothetical regions, some of which were framed 
as comparable to island states, while others were more 
general in their framing and assumptions.
COVID-19 and other relevant respiratory infectious diseases
Included studies assessed the impact of interventions 
aiming to prevent or slow the transmission of COVID-19 
and other infectious respiratory diseases. We identified a 
large number of studies focusing on COVID-19 (n=59); 
we also found studies focusing on SARS (n=11), MERS 
(n=1) and various strains of influenza (n=39). Other 
studies looked at multiple infectious respiratory diseases 
(n=5) or a hypothetical infectious disease with COVID-19 
relevant properties (n=7).
Figure 2 illustrates how the number of publications 
concerned with each disease has developed over time and 
explores where interventions have been implemented. 
As expected, there has been a rapid burst of research 
related to COVID-19 travel restrictions in 2020 (panel 
A), currently consisting mostly of non- peer- reviewed 
preprints. Research on SARS, MERS and influenza travel 
restrictions is more spread over time and also clusters 
around specific outbreaks (eg, SARS 2003; H1N1 influ-
enza 2009) (panel B).
Intervention categories and interventions
The 122 included studies assessed the impact of a wide 
range of travel- related control measures. We classi-
fied these according to broad intervention categories, 
including border closures (n=3), entry/exit screening 
(n=31), travel- related quarantine (n=6), travel bans, such 
as suspension of international flights (n=8), and travel 
restrictions (n=25).
For travel restrictions, a few studies described imposing 
restrictions in relation to the mode of travel (eg, 
restricting air, land or maritime travel); most used the 
term ‘travel restrictions’ without providing any specifica-
tion. However, most of the studies in this category were 
modelling studies, which commonly simulated ‘travel 
restrictions’ as different percentage reductions in the 
travel volume (eg, 50% and 90%).
We identified a relatively large number of studies 
assessing the impact of a bundle of different travel- related 
control measures (eg, entry/exit screening and quaran-
tining all arriving passengers) (n=49). More than half 
of these (n=29) assessed the impact of the lockdown of 
Wuhan (n=29), combining several travel- related measures. 
We classified all of these studies as assessing multiple travel- 
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it was impossible to identify the specific measures assessed 
due to lack of reporting.
Figure 3 visualises the body of evidence according to 
the respective disease, intervention implemented, as well 
as region in which an intervention was implemented. It 
becomes clear that the majority of the evidence assesses 
multiple travel- related control measures to delay or limit 
the progression of COVID-19. The second largest block 
of evidence emerges from studies focusing on various 
influenza strains and the impact of travel restrictions and 
entry/exit screening.
A critical aspect in relation to the likely impact of travel- 
related control measures is the timing of implementa-
tion. Figure 4 (panel A) visualises during which phase of 
an epidemic or pandemic different types of interventions 
addressed by included studies were implemented. With 
respect to the timing of implementation we distinguish 
the following:
 ► Early phase: interventions are implemented at a 
time when there are either no or only singular 
detected/notified cases (ie, all cases are detected 
and quarantined). During this phase, imported cases 
represent the main source of infections.
 ► Local transmission phase: interventions are imple-
mented during more or less widespread human- to- 
human transmission of the disease. During this phase, 
local transmission and imported cases represent 
sources of infections.
 ► Postpeak phase: interventions are implemented 
during/after successful containment of an initial 
outbreak/epidemic/pandemic with the possibility of 
recurrence. During this phase, imported cases may 
again represent a major source of infections.
 ► Unclear phase: the phase of the outbreak/epidemic/
pandemic is not reported or is not directly relevant 
for implementation of the intervention.
Figure 4 (panel A) shows, for example, that many 
interventions, especially those comprising multiple meas-
ures, are implemented when local transmission of the 
disease has already been established. Travel restrictions 
are often employed in the early phase of an epidemic 
or pandemic while entry/exit screening measures tend 
Figure 2 Illustration of the number of studies published over time; the top panel (2002–2020) shows studies focused on SARS, 
MERS, influenza and hypothetical disease with COVID-19 relevant properties, while the bottom panel (2020) shows studies 
focused on COVID-19. The specific disease is indicated by the single letter within the circle. Additionally, the colour represents 
the WHO world region. MERS, Middle East respiratory syndrome; SARS, severe acute respiratory syndrome.
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to be implemented both in the early stages, as well as 
throughout the phases of an epidemic or pandemic. 
Further details on the specific travel- related control meas-
ures reported in each included study and their phase of 
implementation is presented in the online supplemental 
file S6.
Outcome categories and outcomes
We considered studies assessing five broad categories 
of outcomes: infectious disease outcomes, screening 
outcomes, other health outcomes, economic outcomes 
and social outcomes. Identified studies, however, largely 
assessed infectious disease (n=98) and/or screening 
outcomes (n=25). We identified no studies concerned 
with other health outcomes and very few studies assessing 
economic (n=5) or social outcomes (n=1).
Infectious disease outcomes included several types of 
outcomes related to disease timing and transmission, 
including the number or proportion of cases, the number 
or proportion of deaths, the reproduction number, the 
probability of an epidemic, demand for healthcare 
resources and the temporal development of the epidemic. 
Studies assessed various specific outcomes under these 
broader types, for example, ‘time to epidemic peak’ and 
‘delay of epidemic’ both belong to the outcome type 
‘temporal development of the epidemic’. Screening 
outcomes all comprised some form of measuring the 
number and/or proportion of high- risk persons and/
or cases detected. Economic outcomes covered costs 
and industry impact, and social outcomes examined the 
acceptability of travel- related control measures. These 
outcome types as assessed in each study are listed in 
table 1. A comprehensive list of the specific outcomes 
reported for each category and type of outcome and how 
often these were used across the evidence map can be 
found in online supplemental file S7.
Figure 3 Overview of the body of evidence showing the frequency of studies investigating the specific diseases (left column), 
interventions (middle column) and the WHO world regions (right column). MERS, Middle East respiratory syndrome; SARS, 
severe acute respiratory syndrome.
Figure 4 Bubble plots illustrating in included studies (A) during which phase of an epidemic or pandemic different types of 
interventions were implemented and (B) which intervention categories were assessed against different types of outcomes.
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Figure 4 (panel B) illustrates which intervention cate-
gories were assessed by different outcome categories. 
Infectious disease outcomes such as the number or 
proportion of cases, the temporal development of an 
epidemic and the reproduction number were well repre-
sented across all intervention types. Conversely, screening 
outcomes were assessed primarily with respect to entry/
exit screening. The lack of studies assessing economic 
and social outcomes is also clearly visible.
Study types
We included all studies assessing the quantitative impact 
of travel- related control measures on infectious disease, 
screening, economic and social outcomes. As a conse-
quence of this broad scope, included studies employed a 
range of vastly different approaches drawing from the fields 
of infectious disease research, epidemiology, economics, 
biology and mathematics, among others. We categorised 
each study as being either inferential or descriptive. 
Most of the studies we found were inferential in nature 
(n=103), aiming to retrospectively calculate or prospec-
tively forecast the impact of one or multiple travel- related 
control measures on outcomes. The remaining studies 
were descriptive in nature (n=19), aiming to describe the 
impact of control measures through summary statistics 
and/or graphics.
Within these broad categories, however, included 
studies varied greatly with regard to the specific approach 
taken. Inferential studies applied numerous modelling 
and epidemiological techniques; compartmental models, 
such as SIR models (S: susceptible, I: infectious, R: recov-
ered) or SIR model derivatives, were common. Several 
studies also applied spatial models to explore how disease 
transmission moves geographically. Epidemiological time 
series models, as well as other epidemiological modelling 
and testing strategies, were also common. Descriptive 
studies comprised primarily observational studies and 
graphical summary studies, both of which measured and 
reported descriptive summary statistics related to interven-
tion impact. The types of studies illustrated here are not 
exhaustive, and the methodological boundaries between 
the approaches employed are sometimes blurry. In fact, 
several studies apply multiple techniques, combining, for 
example, compartmental and spatial models or compart-
mental and time series models. online supplemental file 
S8 provides a more detailed overview of the study types 
included, along with examples from the included studies.
DISCUSSION
Summary of findings
This evidence map provides a comprehensive overview of 
travel- related control measures available for the control 
of SARS- CoV-2/COVID-19.
Most of the included studies used infectious disease 
or epidemiological modelling methods to examine the 
impact of travel- related control measures on the current 
COVID-19 pandemic. We also identified studies on 
SARS- CoV-1/SARS and influenza, mostly undertaken in 
the context of previous epidemics/pandemics. We found 
very few studies addressing MERS- CoV/MERS. The iden-
tified studies assessing travel- related control measures 
in the context of SARS- CoV-2/COVID-19, were mostly 
preprint publications that have not yet undergone peer 
review and are often characterised by poor reporting and 
conduct.12
Studies were undertaken across the globe. The 
geographical region most represented was WPR, driven in 
part by a number of studies focusing on the Hubei region 
of China and in part by studies across the region during 
the previous SARS- CoV-1/SARS outbreak. AFR and EUR 
were the least represented; we did not identify any studies 
from EMR. Most studies operated at the level of coun-
tries and reported little about specific settings of interest 
(eg, a named airport and a specific country border) or 
the broader implementation context (eg, usual border 
arrangements when control measures are not in place).
Travel- related control measures can be classified as (1) 
border closure, (2) travel bans, (3) travel restrictions, (4) 
entry/exit screening, (5) travel- related quarantine and 
(6) multiple travel- related control measures. Studies were 
identified and mapped for all of these categories. We 
identified a relatively large body of evidence on entry/
exit screening, as well as on travel restrictions. The latter 
also included subnational measures, for example, city- to- 
city travel restrictions across broader regions, making a 
clear distinction from general social distancing measures 
challenging. We also found many studies examining the 
impact of bundles of travel- related control measures. 
Interventions are often poorly described, both in relation 
to the measure itself (eg, border closure) and in relation 
to how the measure is implemented or enforced (eg, 
border patrols, fines and exceptions). Moreover, travel- 
related control measures rarely happen in a vacuum: the 
closer to real- life the intervention (and the study), the 
more cointerventions tend to be involved. This makes 
it very difficult to assess the unique impact of a specific 
measure.
The impact of travel- related control measures in 
controlling geographical spread and overall disease trans-
mission likely varies between early, local transmission and 
postpeak phases of an outbreak/epidemic/pandemic, yet 
reporting of the timing of implementation tends to be 
poor. Most studies focused on the early and local trans-
mission phases; few studies were concerned with the post-
peak phase.
The identified studies almost exclusively examined 
infectious disease and screening outcomes. Surpris-
ingly, we did not identify any study reporting on other 
health outcomes, such as implications for the physical 
and psychosocial health of stranded travellers, of those 
unable to visit family members, of regular commuters 
unable to reach their workplace, of individuals quar-
antined, of people unable to obtain medical treatment 
and other collateral damage (eg, suspended immuni-
sation programmes and impacts on food supply due to 
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limited air, maritime and land travel of either people or 
goods). Only three included studies were concerned with 
economic and social outcomes.
The bulk of the evidence derives from modelling 
studies. In an acute outbreak situation, the time and 
resources that can be dedicated to conducting timely, 
empirical research are limited. Modelling studies vary 
greatly in type (eg, SIR- like models vs time series models) 
and in the underlying assumptions regarding the disease, 
interventions or regions/settings. Additionally, many 
studies do not fall into clean categories, and a single study 
may combine compartmental infectious disease models 
with epidemiological spatial models. They also vary with 
respect to whether and how they have been validated 
through real- life applications.
Gaps in the current evidence base
The evidence map identified several gaps in the evidence 
base related to travel- related control measures that could 
inform future research as well as evidence synthesis. First, 
some regions were under- represented, specifically studies 
conducted or simulated for the countries in the AFR, 
EMR and EUR were lacking. Second, the most commonly 
reported travel- related control measures were entry/exit 
screening and restrictions, which in the context of model-
ling studies were simulated as different levels of travel 
reductions. Thus, the evidence base regarding more strin-
gent measures, such as travel bans and complete border 
closures, remains sparse. Third, our evidence map identi-
fied lack of consideration of the impact of these measures 
on broader health outcomes, such as physical and mental 
health, as well as social and economic outcomes, such 
as cost and burden on communities and socioeconomic 
inequalities. Finally, the key gap relates to the lack of 
empirical studies assessing the impact of travel- related 
control measures, including experimental and quasiex-
perimental approaches.
Methodological limitations of this study
This evidence map was put together over 10 days, and the 
process is thus characterised by several limitations.
While we conducted searches in three major databases 
and two COVID- specific databases, these were mostly 
health centric. We only searched Web of Science—
comprising Science Citation Index Expanded (1900–
present), Social Sciences Citation Index (1900–present) 
and Emerging Sources Citation Index (2015–present)—
to identify social and economic studies. As we identified 
very few economic and social outcomes, it is likely that 
there is another body of evidence to be located with more 
focused searches in specific economic and social science 
databases. In addition, we did not search for grey liter-
ature sources. Furthermore, since COVID-19 initially 
started in Wuhan, China, many studies are published on 
the topic in Chinese journals and databases. Because of 
the language barrier, we did not consider these sources.
The unspecific and inconsistent reporting of primary 
studies with regard to interventions, especially when a 
package of control measures was investigated, sometimes 
made inclusion/exclusion decisions difficult. While we 
developed and calibrated screening guidance to ensure 
consistency among reviewers, it is nevertheless possible 
that we excluded some travel- related control measures 
that were not explicitly described as such. Also, we did 
not undertake double- screening of all studies but only 
reassessed a subset of studies excluded at the full- text 
screening stage. In general, however, we applied a very 
conservative approach to title/abstract, as well as full- text 
screening, where any uncertainties associated with a study 
were marked for further checking by a second reviewer 
and/or for discussion among the whole review team.
We developed and calibrated data extraction guid-
ance to be used consistently by reviewers. Neverthe-
less, we had to refine some categories post hoc. We also 
had a large number of reviewers extracting data, which 
created heterogeneity in the dataset. To address this, a 
second reviewer double- checked all extracted informa-
tion for each of the main domains, that is, all informa-
tion regarding interventions, outcomes and study design. 
Overall, high- quality data extraction was limited by poor 
reporting of the travel- related control measures and 
the specific contexts in which they are implemented in 
primary studies.13
Finally, we did not include travel warning or travel 
advice in the evidence map, which limits the scope of 
this map. While these may be classified as travel- related 
control measures,13 their inclusion would have likely 
broadened our search strategy and prolonged the time-
line of its development. In general, lack of intervention 
specification in the included studies makes it challenging 
to draw clear categories of interventions without poten-
tial overlap (eg, drawing clear distinction between a travel 
ban vs a travel restriction and when these are used only as 
descriptors in the studies without further specification).
Implications for moving forward
An evidence map is not designed to assess the effective-
ness of interventions, in this case the effectiveness of 
travel- related control measures in controlling infectious 
disease spread. The present evidence map sheds light 
on the variety of evidence available with regards to the 
quantifiable impacts of travel- related control measures, 
the outcomes used, as well as the study types employed. 
It thus represents a stepping stone towards a systematic 
review on the effectiveness of all or a subset of travel- 
related control measures.
Given our health- centric searches, we feel confident that 
we have identified most of the available body of evidence 
regarding the quantifiable impacts of travel- related control 
measures on health. In terms of conducting a systematic 
review of effectiveness, it would, however, be advisable to 
undertake additional forward- backward citation searches 
and/or similar studies searches with included studies. We 
identified a number of challenges related to the full anal-
ysis of this evidence base. These include: (1) classifying 
interventions in an appropriate and consistent manner; 
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(2) capturing the details of interventions (eg, compo-
nents, timing and implementation characteristics) and 
cointerventions through an analysis of linked sources 
of evidence; (3) assessing the quality and usefulness of 
different types of studies ranging from simple observa-
tional studies to complex modelling studies; (4) quantita-
tively synthesising this extremely heterogeneous evidence 
base; and (5) dealing with the large number of preprint 
studies and their varying quality. Moving forward with a 
full analysis, we suggest reviewers plan ahead and develop 
strategies on how these challenges can be adequately 
managed. For example, this might entail consideration of 
external sources of evidence beyond scientific databases, 
such as governmental websites on the implementation of 
different travel- related control measures (eg, their timing 
and duration) and other measures in local contexts. To 
contain the COVID-19 pandemic, governments have 
employed a range of public health measures often in a 
bundle, which challenges assessment of the effectiveness 
of any single measure, such as a travel ban. It would there-
fore be important to explicitly document and, where 
possible, assess various combinations of measures imple-
mented—including those related to travel–in future 
research.
Importantly, decisions to maintain or stop travel- 
related control measures are determined by a range of 
factors beyond effectiveness, including legal and human 
rights aspects, as well as considerations of broader health, 
economic and social implications, as well as sociocultural 
and political acceptability. Gathering evidence about 
these broader factors in a systematic manner was beyond 
the scope of the current evidence map; however, such 
aspects might be important to inform decision making. 
Future evidence synthesis would therefore require a 
different scope and a broader search strategy, notably 
encompassing searches in economics and social science 
databases, as well as multidisciplinary databases (eg, 
EconLit, PsycINFO and Scopus).
Twitter Brigitte Strahwald @strahwald
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